Market Snapshot
S&P Futures
3,814.5
Dow Futures
30,961
Nasdaq Futures
11,557.75
Soleno Therapeutics, Inc. (SLNO) stock declined over -3.19% intraday to trade at $0.18 a share on NASDAQ. The stock opened with a loss of -7.22% at $0.179 and touched an intraday high of $0.186, falling -2.70% against the last close of $0.185. The stock went to a low of $0.17 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-01 | $0.179 | $0.186 | $0.17 | $0.179 | 541,100 |
2022-06-30 | $0.194 | $0.195 | $0.175 | $0.185 | 879,100 |
2022-06-29 | $0.18 | $0.221 | $0.175 | $0.197 | 4,591,400 |
2022-06-28 | $0.188 | $0.19 | $0.167 | $0.175 | 578,300 |
2022-06-27 | $0.16 | $0.18 | $0.158 | $0.178 | 1,232,500 |
2022-06-24 | $0.17 | $0.175 | $0.162 | $0.162 | 768,700 |
2022-06-23 | $0.165 | $0.17 | $0.161 | $0.168 | 523,600 |
2022-06-22 | $0.158 | $0.17 | $0.157 | $0.17 | 482,700 |
2022-06-21 | $0.169 | $0.169 | $0.158 | $0.168 | 591,900 |
2022-06-17 | $0.157 | $0.174 | $0.155 | $0.156 | 1,049,800 |
Employees-
Beta0.28
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) stock price is $0.18 as of the last check on Friday, July 1. During the trading session, SLNO stock reached the peak price of $0.186 while $0.17 was the lowest point it dropped to.
The NASDAQ listed SLNO is part of Biotechnology industry that operates in the broader Health Care sector. Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Dr. Anish Bhatnagar M.D.
Pres, CEO, COO & Director
Mr. James H. MacKaness
Chief Financial Officer
Ms. Kristen Yen M.S.
VP of Clinical Operations
Ms. Patricia C. Hirano
VP of Regulatory Affairs
SLNO stock traded closed the last session at $0.179, which is $0.00 or -3.19% lower than its previous close of $0.185. SLNO's current trading price is 37.48% lower than its 52-week high of $1.16 where as its distance from 52-week low of 0.13% is -84.55%.
Number of SLNO employees currently stands at -. SLNO operates from 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065, United States.
Official Webiste of $SLNO is: https://soleno.life
SLNO could be contacted at SLNO operates from 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065, United States, or at phone #650 213 8444 and can also be accessed through its website.
SLNO stock volume for the day was 536,922 shares while in the previous session number of SLNO shares traded was 541,100 . The average number of SLNO shares traded daily for last 3 months was 1.38 Million.
The percentage change in SLNO stock occurred in the recent session was -3.19% while the dollar amount for the price change in SLNO stock was $0.00.
In the recent session, the day high for SLNO stock was $0.186 while the low for SLNO stock touched on the day was $0.17.
The market value of SLNO currently stands at 22.2 Million with its latest stock price at $0.18 and 80.02 Million of its shares outstanding.